Clinical trials: Short Bowel Syndrome (SBS)
Short Bowel Syndrome
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.
- Trial name
- NCT00172185
- Testing
- teduglutide 0.05 mg/kg/d, teduglutide 0.10 mg/kg/d
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 65 people
- Sponsor
- Shire
Short Bowel Syndrome
Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)
Treatment for 3.5-8 weeks with GH (0.05 mg/kg/day) +GLN+Diet, followed by continued compliance to the individualized oral diet and enteral GLN, will result in reduced volume of TPN infusion/week and/or reduced frequency of TPN…
- Trial name
- NCT00742157
- Testing
- Growth Hormone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Nebraska
Short Bowel Syndrome, Malabsorption
Teen and Young Adult Connections for Support From Multidisciplinary Professionals & Peers
12 month study testing mobile delivery of health information and connections to professionals and peers to improve health of teen/young adult HPN users.
- Conditions
- Short Bowel Syndrome, Malabsorption, Malnutrition
- Trial name
- NCT02987569
- Testing
- mConnect plus mobile connections to multidisciplinary professionals & peers, iPad use plus one mobile connections to multidisciplinary professionals & peers
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- University of Kansas Medical Center
Short Bowel Syndrome
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
The purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with Short Bowel Syndrome (SBS).
- Trial name
- EASE SBS 4 (NCT04991311)
- Testing
- Glepaglutide
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021
This study is a 1-year open label extension study to collect long term efficacy and safety data from patients who have completed approximately 2 years of dosing in Study CL0600-021.
- Trial name
- STEPS3 (NCT01560403)
- Testing
- Teduglutide
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shire
Short Bowel Syndrome
A Phase 2 Trial Testing ZP1848 in Patients With SBS
A proof-of-concept, dose finding, controlled, single-center, randomized, double-blind, fixed dose phase 2 trial with ZP1848 in patients with Short Bowel Syndrome.
- Trial name
- glepaglutide (NCT02690025)
- Testing
- ZP1848
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support
The purpose of this study is to determine if an investigational treatment (teduglutide) is safe and effective in Japanese children (age 4 months through 15 years of age) with SBS who are dependent on parenteral support.
- Trial name
- NCT02980666
- Testing
- Teduglutide
- Where
- 5 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Shire
Short Bowel Syndrome
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
- Trial name
- EASE SBS 2 (NCT03905707)
- Testing
- glepaglutide
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 150 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
This study is a 2-year open label extension study to collect long term efficacy and safety data from patients who have completed the 24-weeks of study drug dosing in CL0600-020.
- Trial name
- NCT00930644
- Testing
- teduglutide
- Where
- 23 sites in United States, Canada and 7 more
- Volunteers
- 88 people
- Sponsor
- Shire
Short Bowel Syndrome
SBS DISK- Creation of a Quality of Life Tool for Short Bowel Patients Compared With a Validated Quality of Life Questionnaire (SBS QoL)
Patients with short bowel syndrome have an impact on their quality of life because they need temporary or permanent parenteral nutritional support.
- Trial name
- SBS DISK (NCT06771505)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon